{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:17Z","timestamp":1793662097169,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014173","name":"Shenzhen Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.diabres.2026.113372","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T22:00:43Z","timestamp":1781474443000},"page":"113372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Complementary value of glycated albumin and continuous glucose monitoring for assessing microvascular complications in type 2 diabetes"],"prefix":"10.1016","volume":"238","author":[{"given":"Hang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-161X","authenticated-orcid":false,"given":"Xiaojing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6617-139X","authenticated-orcid":false,"given":"Danfeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diabres.2026.113372_b0005","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113372_b0010","first-page":"S111","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113372_b0015","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dc24-0668","article-title":"Plasma glycated albumin in early pregnancy and gestational diabetes mellitus: a prospective and longitudinal study","volume":"47","author":"Cole","year":"2024","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2026.113372_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108040","article-title":"Glycated albumin as biomarker: evidence and its outcomes","volume":"35","author":"Kohzuma","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2026.113372_b0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2337\/dc23-1276","article-title":"Assessment of glycemic control by continuous glucose monitoring, hemoglobin a1c, fructosamine, and glycated albumin in patients with end-stage kidney disease and burnt-out diabetes","volume":"47","author":"Kaminski","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113372_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113372_b0035","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc25-0595","article-title":"Detecting hyperglycemia using biomarkers versus continuous glucose monitoring","volume":"48","author":"Daya","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113372_b0040","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70073","article-title":"The relationship between glycated albumin and time in tight range in type 2 diabetes","volume":"17","author":"Ni","year":"2025","journal-title":"J Diabetes"},{"issue":"11","key":"10.1016\/j.diabres.2026.113372_b0045","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1210\/clinem\/dgad298","article-title":"Glycated albumin correlates with time-in-range better than HbA1c or fructosamine","volume":"108","author":"Desouza","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113372_b0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jdi.13437","article-title":"Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-D-glucitol","volume":"12","author":"Ohigashi","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"4","key":"10.1016\/j.diabres.2026.113372_b0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.115.015415","article-title":"Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death","volume":"132","author":"Selvin","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.diabres.2026.113372_b0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S2213-8587(13)70199-2","article-title":"Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study","volume":"2","author":"Selvin","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113372_b0065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2337\/db13-0782","article-title":"Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT\/EDIC study","volume":"63","author":"Nathan","year":"2014","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113372_b0070","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113372_b0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2026.113372_b0080","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113372_b0085","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"issue":"4S","key":"10.1016\/j.diabres.2026.113372_b0090","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113372_b0095","first-page":"S246","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2026.113372_b0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.diabres.2026.113372_b0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/biom13050752","article-title":"Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk","volume":"13","author":"Scilletta","year":"2023","journal-title":"Biomolecules"},{"issue":"20","key":"10.1016\/j.diabres.2026.113372_b0110","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2026.113372_b0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.ajkd.2024.02.006","article-title":"Glycated albumin and adverse clinical outcomes in patients with CKD: a prospective cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113372_b0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.diabres.2016.04.018","article-title":"The association of serum glycated albumin with the prevalence of diabetic retinopathy in Korean patients with type 2 diabetes mellitus","volume":"116","author":"Jeon","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.diabres.2026.113372_b0125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/jalm\/jfac006","article-title":"Associations of glycated albumin and hba1c with chronic kidney disease in US adults","volume":"7","author":"Kim","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113372_b0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/dom.70288","article-title":"Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes","volume":"28","author":"Anagnostopoulou","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113372_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002573","article-title":"Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review","volume":"10","author":"Raj","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.diabres.2026.113372_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101616","article-title":"Continuous glucose monitoring\u2011derived time in range and CV are associated with elevated risk of adverse kidney outcomes for patients with type 2 diabetes","volume":"51","author":"Zhang","year":"2025","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113372_b0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13098-023-01071-4","article-title":"Differential correlation between time in range and eGFR or albuminuria in type 2 diabetes","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"10.1016\/j.diabres.2026.113372_b0150","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00125-024-06171-y","article-title":"The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study","volume":"67","author":"De Meulemeester","year":"2024","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113372_b0155","first-page":"2689","article-title":"Continuous glucose monitoring for primary care patients with diabetes: Barriers, facilitators, & resources to support access","volume":"20","author":"Warman","year":"2022","journal-title":"Ann Fam Med"},{"issue":"9","key":"10.1016\/j.diabres.2026.113372_b0160","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1111\/dom.16515","article-title":"Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes","volume":"27","author":"Su","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2026.113372_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107962","article-title":"Time in range correlates glycated albumin measured immediately after 2\u00a0weeks of continuous glucose monitoring","volume":"35","author":"Sakai","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.diabres.2026.113372_b0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/diacare.26.1.163","article-title":"Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy","volume":"26","author":"Cohen","year":"2003","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2026.113372_b0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/dmrr.1117","article-title":"Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy","volume":"26","author":"Rodi\u00f1o-Janeiro","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1016\/j.diabres.2026.113372_b0180","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2337\/dc21-2196","article-title":"Advanced glycation end products predict loss of renal function and high-risk chronic kidney disease in type 2 diabetes","volume":"45","author":"Koska","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2026.113372_b0185","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/dia.2017.0455","article-title":"Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control","volume":"20","author":"Riddlesworth","year":"2018","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:08:36Z","timestamp":1783458516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0168822726002925"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113372","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complementary value of glycated albumin and continuous glucose monitoring for assessing microvascular complications in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113372"}}